Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors ( SSRIs ) and serotonin-norepinephrine reuptake inhibitors ( SNRIs ), and does not resolve in most patients.
Vortioxetine ( Brintellix, Trintellix ), an antidepressant with a multimodal mechanism of action, has shown low rates of sexual dysfunction in previous major depressive disorder ( MDD ) trials.

A study has compared the effects of Vortioxetine and Escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction ( TESD ).

The primary endpoint was change from baseline in the CSFQ-14 total score after 8 weeks of treatment.
The MADRS, CGI, and POMS-brief were used to assess antidepressant efficacy.
Safety was assessed via adverse events, vital signs, electrocardiograms, laboratory values, weight, and physical examination findings.